Latest news
July 25, 2017
Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea
June 30, 2017
Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of…
June 28, 2017
GenePOC Announces an Exclusive Distribution Agreement with Cardinal Health covering the US market
June 20, 2017
Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor
June 15, 2017
Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN
June 1, 2017
Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284